1I8L
 
 | | HUMAN B7-1/CTLA-4 CO-STIMULATORY COMPLEX | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, CYTOTOXIC T-LYMPHOCYTE PROTEIN 4, T LYMPHOCYTE ACTIVATION ANTIGEN CD80, ... | | Authors: | Stamper, C.C, Somers, W.S, Mosyak, L. | | Deposit date: | 2001-03-14 | | Release date: | 2001-04-04 | | Last modified: | 2024-04-03 | | Method: | X-RAY DIFFRACTION (3 Å) | | Cite: | Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses.
Nature, 410, 2001
|
|
1DR9
 | | CRYSTAL STRUCTURE OF A SOLUBLE FORM OF B7-1 (CD80) | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, T LYMPHOCYTE ACTIVATION ANTIGEN | | Authors: | Ikemizu, S, Jones, E.Y, Stuart, D.I, Davis, S.J. | | Deposit date: | 2000-01-06 | | Release date: | 2000-01-10 | | Last modified: | 2021-11-03 | | Method: | X-RAY DIFFRACTION (3 Å) | | Cite: | Structure and dimerization of a soluble form of B7-1.
Immunity, 12, 2000
|
|
8HXA
 | | Cryo-EM structure of MPXV M2 in complex with human B7.1 | | Descriptor: | NFkB inhibitor, T-lymphocyte activation antigen CD80 | | Authors: | Wang, Y, Yang, S, Zhao, H, Deng, Z. | | Deposit date: | 2023-01-04 | | Release date: | 2023-08-30 | | Last modified: | 2023-12-13 | | Method: | ELECTRON MICROSCOPY (3.04 Å) | | Cite: | Structural and functional insights into the modulation of T cell costimulation by monkeypox virus protein M2.
Nat Commun, 14, 2023
|
|
7TPS
 | | Crystal structure of ALPN-202 (engineered CD80 vIgD) in complex with PD-L1 | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-3)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, ... | | Authors: | Demonte, D.W, Maurer, M.F, Akutsu, M, Kimbung, Y.R, Logan, D.T, Walse, B. | | Deposit date: | 2022-01-26 | | Release date: | 2022-03-16 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (3.15 Å) | | Cite: | The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity.
Nat Commun, 13, 2022
|
|
